Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion in Severe/Critical COVID-19 (AP-017)
NCT04839965Phase 2Terminated
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing IV Ampion with IV Placebo (2 arms). Primary endpoint: Number of Participants With Occurrence of Mechanical Ventilation or Death at Day 28. Started Jul 2021; status: terminated.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04839965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839965.